NRSN — Neurosense Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Neurosense Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | C2022 December 31st | C2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.04 | -10.5 | -10.1 | -10.2 | -11.1 |
| Depreciation | |||||
| Non-Cash Items | 2.23 | 1.77 | -0.181 | 0.834 | 2.09 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.273 | 1.09 | 1.91 | -0.781 | 1.34 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -1.54 | -7.62 | -8.35 | -10.1 | -7.67 |
| Capital Expenditures | -0.017 | -0.07 | -0.029 | -0.003 | -0.008 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -3.52 | 3.5 | 0.004 | — |
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.017 | -3.59 | 3.47 | 0.001 | -0.008 |
| Financing Cash Flow Items | 0.8 | -0.096 | -0.364 | -0.391 | -0.121 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 11.9 | 3.77 | 3.98 | 10.9 | 4.43 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 10.4 | -7.52 | -0.903 | 0.738 | -3.21 |